TWST: Would you begin with a brief introduction to your coverage area, including some of the specific names you follow?
Mr. Roden: I cover biotech companies of all cap ranges. There is a little bit of emphasis in our
Pharmaceuticals >> Analyst Interview >> September 17, 2012
Hepatitis C Therapies Propel Growth in Biotech
Matthew Roden is an Executive Director and Senior Analyst at UBS, leading coverage of large- and smid-cap biotechnology stocks. He joined UBS in 2010 and was named as a 2011 Institutional Investor All-America Research Team Rising Star in biotechnology. Previously, Dr. Roden was a lead small- to mid-cap biotech Analyst at Bank of America Merrill Lynch as well as J... More
